Articles tagged with Neuropathic Pain
Researchers have discovered how cone snail venom Vc1.1 works to reduce neuropathic pain by targeting specific calcium channels in neurons. This breakthrough could lead to the development of synthetic versions of Vc1.1 to treat certain types of chronic pain.
A new drug treatment has been found to be effective against chronic pain caused by nerve damage, including post-herpetic neuralgia. Fifty-eight per cent of participants taking the drug found it effective, reducing pain by at least 30 per cent.
Researchers found acupuncture activates ephrin-B/EphB signaling, potentially improving pain and repairing injured nerves. The study provides insight into the mechanisms underlying acupuncture's effects on neuropathic injury and pain.
Neuropathic pain is a daily reality for millions of Americans, but researchers have found a way to protect GABA neurons from oxidative stress, which may help alleviate the condition. By using an antioxidant compound, scientists were able to lower pain behavior and preserve GABA neuron populations.
A Duke University study found that a compound called neuroprotectin D1 can relieve neuropathic pain caused by nerve injuries. The derivative of DHA, a main ingredient of fish oil supplements, inhibits the production of cytokines and chemokines, protecting nerve cells from further damage.
Researchers at UTMB are using gene therapy to target the serotonin 2C receptor in the amygdala to prevent abnormal pain generation and treatment resistance. They aim to develop a permanent solution to neuropathic pain, which affects millions of Americans.
A key protein in Schwann cells is essential for normal interactions between nerve cells and Schwann cells, regulating the steps that lead to nerve regeneration. Deficiency of this protein may lead to chronic neuropathic pain, motivating the development of a small molecule drug to mimic its function.
A large study found that two-thirds of eligible patients experience significant and lasting benefits from deep brain stimulation (DBS) for neuropathic pain. Benefits vary by cause, with improved outcomes seen in patients with amputation and stroke. Continued improvement is observed with longer follow-up.
Using liposomes packed with local anesthetic, researchers at Boston Children's Hospital delayed the rise of neuropathic pain by two days and a month in animal models. The method could potentially allow doctors to stop the cascade of events leading to chronic pain.
Exercise significantly reduces neuropathic pain severity and inflammation-promoting cytokine expression in rats with sciatic nerve injury. This study provides evidence that exercise can be a helpful, non-pharmacological therapy for managing neuropathic pain.
Researchers have successfully transplanted embryonic cells into adult mouse spinal cords to alleviate persistent pain. The study suggests that this approach may not only treat symptoms but also correct underlying disease pathology. This new therapy offers hope for patients with neuropathic pain, a condition with limited treatment options.
Researchers have identified an unexpected source of diabetic neuropathy pain in laboratory rats with diabetes: changes in the structure of dendritic spines. This finding suggests a potential therapeutic strategy by targeting abnormal spines to alleviate pain.
A new drug, BL-7050, is being developed to manage resistant chronic pain caused by nerve or tissue damage. The medication targets potassium channels to prevent hyper-excitability and induce calm in neurons, offering relief to millions of sufferers.
Scientists from Scripps Research Institute have discovered dimethylsphingosine (DMS), a molecule produced at abnormally high levels in the spinal cords of rats with neuropathic pain, which appears to cause pain when injected. Inhibiting DMS production may be a fruitful target for drug development.
Scientists at University of Cambridge identify gene HCN2 as key regulator of chronic pain. The discovery opens up possibility of developing new, targeted pain medications.
A randomized controlled trial found smoked cannabis significantly reduces chronic pain intensity, improving sleep quality and anxiety levels. The study used three different potencies of THC and a placebo, with the highest THC level showing the most significant benefits.
A new study published in The Lancet found that combining gabapentin and nortriptyline is more effective than using either drug alone in reducing neuropathic pain. The treatment resulted in a significant reduction in pain scores, with patients experiencing relief from their symptoms.
A newly discovered compound from a soft coral may hold the key to developing effective treatments for neuropathic pain. The research suggests that inflammation in the nervous system is a major factor in this condition, and the compound has been shown to reduce pain-related activities in isolated microglia and experimental rats.
A new standardized tool for assessing chronic pain has been developed and validated to differentiate between peripheral neuropathic pain and non-neuropathic low back pain. The tool, called STEP, takes just 10-15 minutes to administer and has been shown to have high diagnostic accuracy.
A mouse model of neuropathic pain showed that immune cells producing opioids reduced symptoms, suggesting a novel approach for pain relief. Selectively targeting opioid-containing immune cells may provide natural pain relief and offer a new treatment option.
Researchers discovered that immune cells producing opioids can alleviate neuropathic pain in mice. Meanwhile, a study found that Vitamin D3 might boost the efficacy of cancer immunotherapies by targeting specific immune cells.
Researchers at the University of California, San Diego School of Medicine conducted a double-blind clinical trial to assess the impact of smoked medical cannabis on neuropathic pain in HIV patients. The study showed that reported pain relief was greater with cannabis than with a placebo.
Researchers from the University of California, San Diego, have identified a protein called LRP1 that may help ease neuropathic pain by blocking the response of glial cells. The study found that administering LRP1 into injured peripheral nerves decreased the level and activity of proinflammatory cytokines, leading to reduced pain.
Researchers have discovered a new compound, sLRP1-alpha, that attenuates neuropathic pain in rodents. The study found that sLRP1-alpha reduces inflammation and inhibits pain signals in the nervous system.
Researchers successfully used gene therapy to block pain response in an animal model of neuropathic pain. The study involved delivering a genetically engineered herpes simplex virus to rats with the goal of activating the glycine receptor, which alleviated pain response. This breakthrough suggests that gene therapy may be effective for...
Researchers found a new approach to treating chronic and debilitating neuropathic pain by blocking the alpha9alpha10 nicotinic acetylcholine receptor. The study suggests a previously unrecognized molecular mechanism for treating this condition, which affects hundreds of millions of people worldwide.
Researchers at Johnson & Johnson Pharmaceutical Research & Development have discovered a new molecular mechanism underlying neuropathic pain, which may lead to the development of new treatments. The research focuses on specific types of ion channels called 'pacemaker channels' that initiate constant pain signals to the brain.
New research suggests targeting affected nerves and spinal cords may provide relief from chronic neuropathic pain. The study found changes in spinal cord neurons after sciatic nerve constriction injury, but the exact mechanisms remain unclear.
Microglia have been found to play a crucial role in neuropathic pain by releasing Brain-Derived Neurotropic Factor (BDNF). BDNF disrupts inhibition in the spinal cord, leading to abnormal pain signals. The discovery offers new hope for diagnostics and treatment of chronic pain.
Researchers at the University of Virginia Health System have identified a new type of pain-sensing neuron in rats, which may serve as a target for future therapies to treat neuropathic pain. The T-type calcium channels in these cells may act as a volume control for pain impulses.
The company will use the investment to accelerate its drug development program for neuropathic pain, a prevalent condition affecting an estimated 45% of diabetics and 75% of those over 70. With a significant worldwide market valued at US$3 billion, Spinifex aims to deliver a novel solution to this unmet medical need.
Scientists develop gene transfer technology to block neuropathic pain by delivering a GABA-enhancing gene via a disabled herpes simplex virus. The treatment showed promise in animal studies, with pain-relieving effects lasting up to six weeks. A clinical trial in humans is planned.
The guidelines recommend five medication types to treat neuropathic pain, including gabapentin, lidocaine patches, and narcotics. Neuropathic pain affects 4-6 million people in the US, caused by nerve damage from conditions like shingles, diabetes, and cancer.
A study by Michael DeBaun and colleagues found that children with neuropathic pain require significantly higher doses of morphine and benzodiazepine than those without. Using methadone as an alternative, the team discovered a more effective treatment approach for pain relief in these patients.
A new study found that levorphanol's ability to reduce pain is comparable to tricyclic antidepressants and gabapentin, commonly used drugs for neuropathic pain treatment. High-dose treatment provided greater pain reduction without tolerance, but also led to more side effects and participant dropout.
Neuropathic pain is a complex condition that can be difficult to treat, but research suggests that psychological factors play a crucial role. Dr. Bushnell's work highlights the importance of catching pain early and treating it aggressively, as well as exploring alternative approaches such as meditation and drawing
A recent study published by the American Academy of Neurology found bupropion SR to be clinically effective for treating neuropathic pain. Approximately three-quarters of patients experienced a 30% reduction in pain symptoms with bupropion SR, while those on placebo saw little improvement.